Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latozinemab continuation study in neurodegenerative disease
NCT06111014Phase 3Terminated
- Sponsor
- Alector
- Start
- Dec 2023
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of latozinemab in frontotemporal dementia (FTD), sponsored by Alector. Started Dec 2023; status: terminated.
02
Drugs
latozinemab
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT06111014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06111014.